Structure of Osimertinib
CAS No.: 1421373-65-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. It overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Synonyms: AZD-9291; Mereletinib
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma
Guo, Tongxuan ; Wu, Changyong ; Zhang, Junhao ; Yu, Jiefeng ; Li, Guoxi ; Jiang, Hongyan , et al.
Abstract: Background: Glioblastoma multiforme (GBM) is a devastating disease that lacks efective drugs for targeted therapy. Previously, we found that the third-generation epidermal growth factor receptor (EGFR) inhibitor AZD-9291 persistently blocked the activation of the ERK pathway but had no inhibitory efect on the phosphoinositide 3-kinase (PI3K)/Akt pathway. Given that the PI3K inhibitor GDC-0084 is being evaluated in phase I/II clinical trials of GBM treatment, we hypothesized that combined inhibition of the EGFR/ERK and PI3K/Akt pathways may have a synergistic efect in the treatment of GBM. Methods: The synergistic efects of cotreatment with AZD-9291 and GDC-0084 were validated using cell viability assays in GBM and primary GBM cell lines. Moreover, the underlying inhibitory mechanisms were assessed through colony formation, EdU proliferation, and cell cycle assays, as well as RNA-seq analyses and western blot. The therapeutic efects of the drug combination on tumor growth and survival were investigated in mice bearing tumors using subcutaneously or intracranially injected LN229 xenografts. Results: Combined treatment with AZD-9291 and GDC-0084 synergistically inhibited the proliferation and clonogenic survival, as well as induced cell cycle arrest of GBM cells and primary GBM cells, compared to monotherapy. Moreover, AZD-9291 plus GDC-0084 combination therapy signifcantly inhibited the growth of subcutaneous tumors and orthotopic brain tumor xenografts, thus prolonging the survival of tumor-bearing mice. More importantly, the combination of AZD-9291 and GDC-0084 simultaneously blocked the activation of the EGFR/MEK/ERK and PI3K/AKT/mTOR signaling pathways, thereby exerting signifcant antitumor activity. Conclusion: Our fndings demonstrate that the combined blockade of the EGFR/MEK/ERK and PI3K/AKT/mTOR pathways is more efective against GBM than inhibition of each pathway alone, both in vitro and in vivo. Our results suggest that AZD-9291 combined with GDC-0084 may be considered as a potential treatment strategy in future clinical trials.
Show More >
Keywords: Glioblastoma ; AZD-9291 ; GDC-0084 ; Combination therapy ; Synergistic inhibition
Show More >
| CAS No. : | 1421373-65-0 |
| Formula : | C28H33N7O2 |
| M.W : | 499.61 |
| SMILES Code : | C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O |
| Synonyms : |
AZD-9291; Mereletinib
|
| MDL No. : | MFCD27988062 |
| InChI Key : | DUYJMQONPNNFPI-UHFFFAOYSA-N |
| Pubchem ID : | 71496458 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
| Target |
|
In Vitro:
| Concentration | Treated Time | Description | References |
| H1975 | 1 μM | 9 days | Generate osimertinib-resistant cell lines | Nat Med. 2019 Jan;25(1):111-118. |
| PC9 | 1 μM | 9 days | Generate osimertinib-resistant cell lines | Nat Med. 2019 Jan;25(1):111-118. |
| HCC827 | 100 nM | 21 days | To observe the metabolic changes in osimertinib-tolerant cells, significant changes in metabolite levels were found | Nat Metab. 2019 Apr;1(4):460-474. |
| HCC827 | 160 nM | 2–3 weeks | To observe the survival of cells under continuous dosing, it was found that some cells survived for 2–3 weeks at 160 nM osimertinib | Nat Metab. 2019 Apr;1(4):460-474. |
| HCC827 | 0.01–2 µM | 3 days | To observe the acute treatment response of cells to osimertinib, it was found that a subpopulation of tumor cells survived cytotoxic doses | Nat Metab. 2019 Apr;1(4):460-474. |
| HCC827 | 2 nM | 72 h | To evaluate the antiproliferative activity of ASK120067 on EGFR exon19 deletion mutant cells, the results showed that ASK120067 significantly inhibited the proliferation of HCC827 cells with an IC50 value of 2 nM. | Mol Cancer. 2020 May 13;19(1):90. |
| PC-9 | 6 nM | 72 h | To evaluate the antiproliferative activity of ASK120067 on EGFR exon19 deletion mutant cells, the results showed that ASK120067 significantly inhibited the proliferation of PC-9 cells with an IC50 value of 6 nM. | Mol Cancer. 2020 May 13;19(1):90. |
| NCI-H1975 | 12 nM | 72 h | To evaluate the antiproliferative activity of ASK120067 on EGFR T790M mutant cells, the results showed that ASK120067 significantly inhibited the proliferation of NCI-H1975 cells with an IC50 value of 12 nM. | Mol Cancer. 2020 May 13;19(1):90. |
| HCC2935 | 500 nM | 21 days | To identify gene expression changes in osimertinib DTPs, finding distinct gene expression patterns in DTPs compared to acute treatment. | NPJ Precis Oncol. 2022 Dec 27;6(1):95. |
| HCC827 | 500 nM | 21 days | To identify gene expression changes in osimertinib DTPs, finding distinct gene expression patterns in DTPs compared to acute treatment. | NPJ Precis Oncol. 2022 Dec 27;6(1):95. |
| H1975 | 500 nM | 21 days | To identify gene expression changes in osimertinib DTPs, finding distinct gene expression patterns in DTPs compared to acute treatment. | NPJ Precis Oncol. 2022 Dec 27;6(1):95. |
| PC9 | 500 nM | 21 days | To identify gene expression changes in osimertinib DTPs, finding distinct gene expression patterns in DTPs compared to acute treatment. | NPJ Precis Oncol. 2022 Dec 27;6(1):95. |
| DFCI161 | 1 μM | 16 h | To evaluate the effect of Osimertinib on downstream signaling pathways in DFCI161 cells, results showed that single-agent MET inhibitor was sufficient to inhibit downstream Akt and ERK1/2 phosphorylation. | Sci Transl Med. 2021 Sep;13(609):eabb3738. |
| DFCI81 | 1 μM | 16 h | To evaluate the effect of Osimertinib on downstream signaling pathways in DFCI81 cells, results showed that single-agent MET inhibitor was sufficient to inhibit downstream Akt and ERK1/2 phosphorylation. | Sci Transl Med. 2021 Sep;13(609):eabb3738. |
In Vivo:
| Administration | Dosage | Frequency | Description | References |
| Mice | PC9-OR cell xenograft model | Oral | 5 mg/kg | Once daily for 71 days | Evaluate the tumor growth inhibitory effect of osimertinib in combination with Aurora kinase inhibitors | Nat Med. 2019 Jan;25(1):111-118. |
| Mice | Subcutaneous tumor model | Subcutaneous injection | 100 nM | 21 days | To observe the metabolic changes in osimertinib-tolerant cells, significant changes in metabolite levels were found | Nat Metab. 2019 Apr;1(4):460-474. |
| BALB/c nude mice | NCI-H1975 xenograft model | Oral | 1, 5, 10 mg/kg | Once daily for 21 days | To evaluate the in vivo antitumor activity of ASK120067 in the NCI-H1975 xenograft model, the results showed that ASK120067 dose-dependently inhibited tumor growth, with a tumor growth inhibition (TGI) rate of 99.3% at the 10 mg/kg dose. | Mol Cancer. 2020 May 13;19(1):90. |
| Mice | H1975 xenograft model | Oral | 25 mg/kg | Once daily for 3 weeks | To evaluate the delay in tumor regrowth with Osimertinib in combination with AZD2811 (AURKB inhibitor). | NPJ Precis Oncol. 2022 Dec 27;6(1):95. |
| Mice | Non-small cell lung cancer xenograft model | Oral | 5 mg/kg | Once daily for 95 days | To investigate the anti-tumor effects and resistance mechanisms of Osimertinib in EGFR L858R and T790M mutant xenograft models. Results showed that Osimertinib significantly inhibited tumor growth initially, but resistance developed after prolonged treatment, associated with secondary mutations in BRAF and PIK3C2A and decreased frequencies of EGFR L858R and T790M mutations. | Cancer Commun (Lond). 2018 May 9;38(1):19 |
| Mice | Orthotopic NSCLC model | Oral | 3.125 mg/kg | Once daily, 5/7 days | To evaluate the combination of osimertinib and AZ1366 for tumor control and survival improvement in Wnt-responsive tumors. Results showed that the combination of osimertinib and AZ1366 significantly improved survival in Wnt-responsive HCC4006 and H1650 cell lines. | Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. |
| Mice | PDX model | Oral | 25 mg/kg | Once daily for 28 days | To evaluate the antitumor efficacy of Osimertinib in PDX models, results showed that single-agent MET inhibitor was sufficient to inhibit tumor growth, and the addition of an EGFR inhibitor did not significantly enhance efficacy. | Sci Transl Med. 2021 Sep;13(609):eabb3738. |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT05103605 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | 2026-01-15 | Research Site, Abbeville Cedex... More >>, France|Research Site, Aix En Provence Cedex 1, France|Research Site, Angers Cedex 01, France|Research Site, Antibes Cedex, France|Research Site, Avignon Cedex 9, France|Research Site, Bastia Cedex, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Bourg En Bresse, France|Research Site, Brest, France|Research Site, Cannes Cedex, France|Research Site, Chambery Cedex, France|Research Site, Chauny Cedex, France|Research Site, Cholet, France|Research Site, Clermont-ferrand, France|Research Site, Colmar Cedex, France|Research Site, Contamine-sur-arve, France|Research Site, Creteil, France|Research Site, Elbeuf Cedex, France|Research Site, Epagny METZ Tessy, France|Research Site, Evreux, France|Research Site, La Roche Sur Yon, France|Research Site, Libourne, France|Research Site, Limoges Cedex, France|Research Site, Lyon, France|Research Site, Marseille Cedex 08, France|Research Site, Marseille, France|Research Site, Meaux Cedex, France|Research Site, Mulhouse, France|Research Site, Orleans, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Quimper, France|Research Site, Reims Cedex, France|Research Site, Rouen Cedex, France|Research Site, Saint Denis, France|Research Site, Saint Pierre, France|Research Site, Saint Priest En Jarez Cedex, France|Research Site, Saint-gregoire, France|Research Site, Saint-quentin Cedex, France|Research Site, Toulon Cedex 9, France|Research Site, Toulouse Cedex 9, France|Research Site, Valenciennes, France|Research Site, Vannes, France|Research Site, Villefranche-sur-saone, France|Research Site, Villenave-dornon, France|Research Site, Villeurbanne, France Less << | |
| NCT04233021 | Non Small Cell Lung Cancer Met... More >>astatic|Leptomeningeal Metastasis|Brain Metastases|EGFR Activating Mutation Less << | PHASE2 | COMPLETED | 2024-12-27 | Centre Hospitalier Aix-Pertuis... More >>, Aix-en-Provence, 13616, France|CHU Amiens - Groupe Hospitalier Sud, Amiens, 80054, France|Centre Paul Papin, Angers, 49055, France|H?pital privé d'Antony, Antony, 92166, France|Institut Sainte Catherine, Avignon, 84918, France|Centre Hospitalier de la C?te Basque, Bayonne, 64100, France|CHU Besan?on - H?pital J. MINJOZ, Besan?on, 25030, France|Groupe Hospitalier Saint André, Bordeaux, 33075, France|AP-HP H?pital Ambroise Paré, Boulogne, 92104, France|CHU C?te de Nacre, Caen, 14000, France|H?pital Louis Pasteur, Colmar, 68024, France|Centre Hospitalier Intercommunal de Créteil, Créteil, 94000, France|CHU H?pital du Bocage, Dijon, 21079, France|Chu Grenoble, Grenoble, 38043, France|Centre Hospitalier Général, Le Mans, 72037, France|H?pital Calmette, Lille, 59037, France|CHU Dupuytren, Limoges, 87042, France|Institut Paoli Calmettes, Marseille, 13273, France|Marseille H?pital Nord, Marseille, 13915, France|CHU Montpellier, Montpellier, 34295, France|Centre Hospitalier Régional - H?pital de la Source, Orléans, 45000, France|AP-HP H?pital Cochin, Paris, 75014, France|AP-HP H?pital Bichat, Paris, 75877, France|Centre Hospitalier Général - Pau, Pau, 64000, France|Lyon - URCOT Centre Hospitalier Universitaire, Pierre-Bénite, 69310, France|CHU de la Réunion - Site Felix Guyon, Saint-Denis, 97400, France|Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, 44805, France|CHU de La Réunion-Site Sud, Saint-Pierre, 97448, France|Nouvel H?pital Civil - H?pitaux Universitaires de Strasbourg, Strasbourg, 67091, France|H?pital Foch, Suresnes, 92151, France|HIA Sainte-Anne, Toulon, 83800, France|H?pital Larrey, Toulouse, 31059, France|CHU Bretonneau, Tours, 37044, France|Valenciennes Clinique PRIV, Valenciennes, 59300, France|Centre Hospitalier de Villefranche-sur-Sa?ne, Villefranche-sur-Sa?ne, 69655, France|Gustave Roussy, Villejuif, 94805, France Less << |
| NCT05546866 | Non-small Cell Lung Cancer | PHASE2 | ACTIVE_NOT_RECRUITING | 2029-06-30 | Research Site, Beijing, 100730... More >>, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610041, China|Research Site, Fuzhou, 350011, China|Research Site, Guangzhou, 510080, China|Research Site, Kunming, 650118, China|Research Site, Ningbo, 315010, China|Research Site, Shijiazhuang, 050051, China|Research Site, Suzhou, 215006, China|Research Site, Tianjin, 300060, China Less << |
| NCT06206850 | Non-squamous NSCLC | PHASE2 | RECRUITING | 2030-01-01 | Sheba Medical Center, Jusidman... More >> Cancer Center, Ramat Gan, 5590000, Israel|Sheba Medical Center, Ramat-gan, 522651, Israel Less << |
| NCT06477055 | Non-small Cell Lung Cancer | PHASE2 | NOT_YET_RECRUITING | 2027-06-15 | - |
| NCT04391283 | Carcinoma, Non-Small-Cell Lung | UNKNOWN | 2025-12-24 | The First Affiliated Hospital ... More >>of College of Medicine Zhejiang University, Hangzhou, Zhejiang, 310000, China Less << | |
| NCT03535363 | NSCLC|Non-small Cell Lung Canc... More >>er Less << | PHASE1 | COMPLETED | 2022-04-01 | Maimi Cancer Institute - Bapti... More >>st Health South Florida, Miami, Florida, 33176, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, 44195, United States Less << |
| NCT05785208 | Non Small Cell Lung Cancer | PHASE4 | RECRUITING | 2025-10-31 | Azienda Ospedaliero-Universita... More >>ria Ospedali Riuniti, Ancona, 60020, Italy|IRCCS Istituto Tumori Giovanni Paolo II, Bari, 70124, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, 50134, Italy|Ospedale Universitario di Parma, Parma, 44129, Italy|Ospedale San Camillo de Lellis, Rieti, 02100, Italy|Università Policlinico Tor Vergata, Rome, 00133, Italy|Policlinico Umberto I, Rome, 00161, Italy|Fondazione Policlinico Gemelli IRCCS, Rome, 00168, Italy|Ospedale San Giovanni-Addolorata, Rome, 00184, Italy|Ospedale San Luigi, Turin, 10043, Italy|Università degli Studi di Verona, Verona, 37129, Italy Less << |
| NCT03219970 | Non-small Cell Lung Cancer | COMPLETED | 2020-10-28 | Pamela Youde Nethersole Easter... More >>n Hospital, Hong Kong, China|Prince of wales hospital, Hong Kong, China|Queen Mary Hospital, Hong Kong, China|Tuen Mun Hospital, Hong Kong, China Less << | |
| NCT02841579 | Non-Small Cell Lung Cancer | PHASE2 | COMPLETED | 2020-02-14 | MedSIR Investigative Site, Bar... More >>celona, 08026, Spain|MedSIR Investigative Site, Barcelona, 08028, Spain|MedSIR Investigative Site, Bilbao, 48903, Spain|MedSIR Investigative Site, La Coru?a, 15706, Spain|MedSIR Investigative Site, Madrid, 28006, Spain|MedSIR Investigative Site, Málaga, 29010, Spain|MedSIR Investigative Site, Valencia, 46015, Spain Less << |
| NCT03586453 | Carcinoma, Non-Small-Cell Lung | PHASE2 | ACTIVE_NOT_RECRUITING | 2027-03-01 | Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
| NCT05629234 | Cancer | PHASE3 | ACTIVE_NOT_RECRUITING | 2025-02-21 | Research Site, Beijing, 100142... More >>, China|Research Site, Chongqing, 400042, China|Research Site, Shanghai, 200433, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou, 450008, China|Research Site, Villejuif Cedex, 94805, France|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Dong-gu, 44033, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Georgetown, 10450, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuantan, 25100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Szczecin, 70-419, Poland|Research Site, Kaohsiung, 83301, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Tainan, 736, Taiwan|Research Site, Taipei, 112201, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Nottingham, NG5 1PB, United Kingdom Less << |
| NCT03790397 | Non Small Cell Lung Cancer | COMPLETED | 2020-04-01 | Hospital Universitario Central... More >> de Asturias, Oviedo, Asturias, 33011, Spain|ICO Badalona, Badalona, Barcelona, 08916, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, Galicia, 15706, Spain|Complejo Hospitalario Universitario A Coru?a, A Coru?a, La Coru?a, 15006, Spain|Hospital Universitario Dr. Negrín, Las Palmas De Gran Canaria, Las Palmas, 35010, Spain|Hospital Príncipe de Asturias, Alcalá De Henares, Madrid, 28805, Spain|Hospital Universitario de Getafe, Getafe, Madrid, 28905, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Mallorca, 07120, Spain|Hospital Universitario Son Llàtzer, Palma De Mallorca, Mallorca, 07198, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, 36036, Spain|Hospital Lluís Alcanyís, Xàtiva, Valencia, 46800, Spain|Hospital General de Albacete, Albacete, 02006, Spain|Hospital General Universitario Alicante, Alicante, 03010, Spain|Hospital de Sant Pau, Barcelona, 08041, Spain|Hospital Universitario de Burgos, Burgos, 09006, Spain|Hospital Dr. Josep Trueta, Girona, 17007, Spain|Hospital Universitario de Guadalajara, Guadalajara, 19002, Spain|Complejo Hospitalario de Jaén, Jaén, 23007, Spain|Complejo Asistencial Universitario de León, León, 24071, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital Ramón y Cajal, Madrid, 28034, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario Puerta de Hierro, Madrid, 28222, Spain|Hospital General Universitario de Málaga, Málaga, 29010, Spain|Hospital Clínico de Salamanca, Salamanca, 37007, Spain|Hospital Virgen del Rocío, Sevilla, 41013, Spain|Hospital Virgen de la Salud, Toledo, 45071, Spain|Hospital Universitari i Politécnic La Fe, Valencia, 46009, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, 47003, Spain|Hospital Clínico Lozano Blesa, Zaragoza, 50009, Spain Less << | |
| NCT05421936 | Carcinoma, Non-Small-Cell Lung... More >>|Genes, erbB-1 Less << | SUSPENDED | 2025-09-24 | Sheba Medical Centre, Ramat Ga... More >>n, 5265601, Israel Less << | |
| NCT06383728 | Lung Cancer|Carcinoma, Squamou... More >>s Cell Less << | PHASE2 | RECRUITING | 2029-04-30 | The First Affiliated Hospital ... More >>of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China Less << |
| NCT03810066 | NSCLC|EGFR T790M|FDG-PET | PHASE2 | COMPLETED | 2022-09-30 | Prof. Dr. med. Martin Schuler,... More >> Essen, NRW, 45147, Germany Less << |
| NCT06436144 | Non Small Cell Lung Cancer|EGF... More >>R Gene Mutation|Non Small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV Less << | PHASE2 | NOT_YET_RECRUITING | 2025-12-29 | - |
| NCT03853551 | Non Small Cell Lung Cancer (NS... More >>CLC) Less << | PHASE4 | COMPLETED | 2020-04-15 | Research Site, Hyderabad, 5000... More >>34, India|Research Site, Hyderabad, 500096, India|Research Site, Kolkata, 700160, India|Research Site, Mumbai, 400012, India|Research Site, Mumbai, 400053, India|Research Site, New Dehli, 110029, India|Research Site, New Delhi, 110085, India Less << |
| NCT04816838 | Non Small Cell Lung Cancer | RECRUITING | 2025-10-25 | Yonsei University Health Syste... More >>m, Severance Hospital, Seoul, Korea, Republic of Less << | |
| NCT05458726 | EGFR T790M|Osimertinib|Non-sma... More >>ll Cell Lung Cancer|ddPCR Less << | PHASE2 | UNKNOWN | 2022-10-31 | Junling Li, Beijing, Beijing, ... More >>100021, China Less << |
| NCT05513664 | Locally Advanced or Metastatic... More >> Non-Small Cell Lung Cancer|EGFR Exon20 Insertion Mutations Less << | UNKNOWN | 2025-08-23 | Affiliated Hospital of Hebei U... More >>niversity, Baoding, China|Beijing Cancer Hospital, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, China|Chongqing Cancer Hospital, Chongqing, China|Southwest Hospital of Army Medical University, Chongqing, China|Fujian Cancer Hospital, Fuzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China|Anhui Cancer Hospital, Hefei, China|Shandong Cancer Hospital, Jinan, China|Nanjing Chest Hospital, Nanjing, China|Fudan University Cancer Hospital, Shanghai, China|Shanghai Chest Hospital, Shanghai, China|Shanxi Provincial People's Hospital, Shanxi, China|The Fourth Hospital of Hebei Medical University, Shijia Zhuang, China|West China Hospital of Sichuan University, Sichuan, China|Shanxi Cancer Hospital, Taiyuan, China|Huazhong University of Science Tongji Hospital, Tongji Medical College, Wuhan, China|Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, China|Henan Cancer Hospital, Zhengzhou, China Less << | |
| NCT02769286 | Lung Neoplasms|EGFR Gene Mutat... More >>ions Less << | PHASE2 | COMPLETED | 2025-05-20 | Chonnam National University Hw... More >>asun Hospital, Hwasun, Jeonnam, 58128, Korea, Republic of Less << |
| NCT03394118 | NSCLC | PHASE2 | COMPLETED | 2021-04-08 | Asan Medical Center, Seoul, Ko... More >>rea, Republic of Less << |
| NCT05686434 | NSCLC, Stage I | PHASE2 | RECRUITING | 2029-10-14 | Tianjin Medical University Can... More >>cer Institute & Hospital, Tianjin, Tianjin, 300060, China Less << |
| NCT03239340 | EGFR Mutation Positive Locally... More >> Advanced or Metastatic Non-Small Cell Lung Cancer Less << | PHASE2 | COMPLETED | 2023-09-19 | Research Site, Athens, Georgia... More >>, 30607, United States|Research Site, Atlanta, Georgia, 30307, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Brescia, 25100, Italy|Research Site, Meldola, 47014, Italy|Research Site, Monza, 20900, Italy|Research Site, Parma, 43126, Italy|Research Site, Roma, 00152, Italy|Research Site, Terni, 05100, Italy|Research Site, Busan, 47392, Korea, Republic of|Research Site, Cheongiu, 28644, Korea, Republic of|Research Site, Seongnam, 13620, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 135-710, Korea, Republic of|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuantan, 25100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Lembah Pantai, 59100, Malaysia|Research Site, Pulau Pinang, 10450, Malaysia|Research Site, A Coru?a, 15006, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, Madrid, 28046, Spain|Research Site, Sevilla, 41009, Spain Less << |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.00mL 0.40mL 0.20mL |
10.01mL 2.00mL 1.00mL |
20.02mL 4.00mL 2.00mL |
|